Janux Therapeutics Inc (JANX)
47.11
-0.40
(-0.84%)
USD |
NASDAQ |
May 17, 16:00
47.11
0.00 (0.00%)
After-Hours: 20:00
Janux Therapeutics Research and Development Expense (Annual): 54.92M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 54.92M |
| December 31, 2022 | 53.44M |
| December 31, 2021 | 26.24M |
| Date | Value |
|---|---|
| December 31, 2020 | 3.041M |
| December 31, 2019 | 2.999M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
2.999M
Minimum
2019
54.92M
Maximum
2023
28.13M
Average
26.24M
Median
2021
Research and Development Expense (Annual) Benchmarks
| Viking Therapeutics Inc | 63.81M |
| Equillium Inc | 37.04M |
| Minerva Neurosciences Inc | 12.71M |
| Arvinas Inc | 379.70M |
| Calidi Biotherapeutics Inc | 13.01M |